sulfazecin: beta-lactam antibiotic from Pseudomonas; RN given refers to (D-Ala)-(R)-isomer; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 9908721 |
| SCHEMBL ID | 209149 |
| MeSH ID | M0091768 |
| Synonym |
|---|
| sulfazecin |
| d-alaninamide, d-gamma-glutamyl-n-(3-methoxy-2-oxo-1-sulfo-3-azetidinyl)-, (r)- |
| antibiotic em 5210 |
| antibiotic g 6302 |
| 77912-79-9 |
| unii-x83nw9a0y8 |
| x83nw9a0y8 , |
| SCHEMBL209149 |
| DTXSID40228544 |
| sq 26445 |
| C20927 |
| sulfazecin, (+)- |
| d-alaninamide, d-.gamma.-glutamyl-n-((3r)-3-methoxy-2-oxo-1-sulfo-3-azetidinyl)- |
| g-6302 |
| antibiotic em-5210 |
| sulfazecin [mi] |
| sulfazecin free acid |
| n5-((r)-1-(((r)-3-methoxy-2-oxo-1-sulfoazetidin-3-yl)amino)-1-oxopropan-2-yl)-d-glutamine |
| 77912-79-9 (free acid) |
| Q27293666 |
| (2r)-2-amino-5-[[(2r)-1-[[(3r)-3-methoxy-2-oxo-1-sulfoazetidin-3-yl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid |
| AKOS040749577 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 8 (72.73) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (27.63) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (9.09%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (90.91%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||